About NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial (NDUFA10) is a protein
from Homo sapiens identified by UniProt accession
O95299, 355 residues long.
MolForge cross-references it against 0 known binders and
243 disease associations.
Target properties
| Protein name | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial |
| UniProt accession | O95299 |
| Gene | NDUFA10 |
| Organism | Homo sapiens |
| Length | 355 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (243)
Diseases linked to this target (Open Targets).
- Leigh syndrome · score 0.67
- mitochondrial complex I deficiency · score 0.63
- type 2 diabetes mellitus · score 0.61
- diabetes mellitus · score 0.60
- polycystic ovary syndrome · score 0.60
- schizophrenia · score 0.59
- type 1 diabetes mellitus · score 0.58
- gestational diabetes · score 0.58
- obesity · score 0.57
- prediabetes syndrome · score 0.56
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95299-F1 | alphafold | PREDICTED | 84.01 | — |
Amino-acid sequence (355 residues)
MALRLLKLAA TSASARVVAA GAQRVRGIHS SVQCKLRYGM WHFLLGDKAS KRLTERSRVI TVDGNICTGK GKLAKEIAEK LGFKHFPEAG IHYPDSTTGD GKPLATDYNG NCSLEKFYDD PRSNDGNSYR LQSWLYSSRL LQYSDALEHL LTTGQGVVLE RSIFSDFVFL EAMYNQGFIR KQCVDHYNEV KSVTICDYLP PHLVIYIDVP VPEVQRRIQK KGDPHEMKIT SAYLQDIENA YKKTFLPEMS EKCEVLQYSA REAQDSKKVV EDIEYLKFDK GPWLKQDNRT LYHLRLLVQD KFEVLNYTSI PIFLPEVTIG AHQTDRVLHQ FRELPGRKYS PGYNTEVGDK WIWLK
Explore NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets